Amarin Corp Plc (AMRN)

[studythosestocks]

Thanks for your kind words and understanding. I don't know if this will help either one of us or not but I went ahead and transcribed Budoff's words for the final result slide and conclusion slide to give us all a little more to digest if that helps. Others may have already answered this question so disregard if they have since haven't had a chance to go through posts. I put bold on some points that stood out to me.

This is our final results. Here you can see change in plaque quantity based on the treatment group. In red is the placebo group, in blue is the icosapent ethyl patients. Above the line demonstrates progression from scan one to final follow up. And below the line represents regression or less plaque on follow up than baseline scan. The primary endpoint is represented on the left: low attenuation plaque or what we would call vulnerable plaque and you can see marked progression in the placebo group with a 109% increase in plaque volumes over the course of 18 months.
Keep in mind that both groups Icosapent Ethyl and Placebo were all on statin therapy during the duration of the study. You can see generally that the placebo group had progression of atherosclerosis with more fibrofatty plaque, more calcified plaque, noncalcified plaque and total plaque volume.
The IE group largely had regression, less plaque on follow up with less plaque in the primary endpoint Low Attenuation but also FibroFatty, fibrous total noncalcified plaque and total plaque. Here demonstrates the plaque characteristics by treatment group. Here you can see baseline plaque for each of the different plaque components. This is measured in volume or mm cubed and then the follow up variables. …….
In conclusion, Compared with placebo IE 4g/day significantly reduced multiple plaque components including vulnerable (low attenuated) plaque.
Very early effect (9 months), with sustained and increasing significance by 18 months.
To the best of our knowledge, this is the first elegant marriage of clinical trial results (Reduce-It) and imaging (Evaporate), demonstrating consistent benefits of IE on both outcomes and plaque reduction.
These data highlight the early and substantial impact of IE on the atherothrombotic burden in the at risk group.